Therapeutic attitudes and clinical global impression: A 2-year follow-up study of 33 outpatients with a mental disorder in treatment with paliperidone palmitate

2016 ◽  
Vol 33 (S1) ◽  
pp. S616-S617
Author(s):  
M.D. Perez Lopez ◽  
M. Soto laguna ◽  
J. Prados Gomez ◽  
I. Zarranz Herrera Oria ◽  
R. Perez Asenjo ◽  
...  

IntroductionMaintaining antipsychotic therapy in mental disorder is important in preventing relapse, rehospitalization, and suicide. Lack of awareness of illness may be a leading cause for non-adherence. Long-acting depot can prevent non- adherence and thus potentially contribute to better patient outcomes.ObjectiveThe aim of this prospective, observational, non interventional 2-year-long study is to assess severity and post-intervention changes and attitudes toward medication of a group of patients treated paliperidone palmitate (PP).MethodsThirty-three outpatients stabilised with PP during the last 24 months. Inclusion criteria were: patients’ age (> 18 years), a diagnosis of schizophrenia, bipolar disorder, schizoaffective disorder stabilised during the last 12 months with PP, without a diagnostics from axis I or II (except for nicotine of caffeine) and able to sign the inform consent. Data collected: general sociodemographic and clinical data (age, sex, level of education, socioeconomic situation, family support, psychiatric diagnosis, years of evolution, use/abuse of substances, treatment, previous and later number of hospitalisations. Evaluations included disease severity (Clinical Global Impression-Severity (CGI-S) and Drug Attitude Inventory, (DAI)).ResultsThirty-threeoutpatients were followed during 24 months [mean dose 132,58 (44,4) mg], 75,8% were men, age 45,05 years old, 87,8% with a diagnoses of paranoid schizophrenia. Antipsychotic monotherapy increased over the time with PP. Significant improvements were observed on both Clinical Global Impression and Drug Attitude Inventory. The number of rehospitalizations and mean stays decreased from the beginning until the end of these 24 months.ConclusionsOur results suggest an improvement in the patient's clinical vision and attitude towards medication with long-acting depot.Disclosure of interestThe authors have not supplied their declaration of competing interest.

2015 ◽  
Author(s):  
Jaafar Nakhli ◽  
Badii Amamou ◽  
Salem Mlika ◽  
Saoussen Bouhlel ◽  
Marwan Trifi ◽  
...  

2000 ◽  
Vol 10 ◽  
pp. 298-299 ◽  
Author(s):  
I. García Cabeza ◽  
J.A. Hormaechea Beldarrain ◽  
M. Sanz Amador ◽  
C. Arango López ◽  
M. González de Chávez

2013 ◽  
Vol 23 (10) ◽  
pp. 1296-1299 ◽  
Author(s):  
Sigrid Stjernswärd ◽  
Karin Persson ◽  
René Nielsen ◽  
Eva Tuninger ◽  
Sten Levander

2021 ◽  
Vol 11 (5) ◽  
pp. 305-310
Author(s):  
Christopher Evernden ◽  
Irene Giang ◽  
Mariah Anderson

Abstract International schizophrenia guidelines endorse seeking the patient's preference for guiding antipsychotic therapy. There exists a small niche of patients who prefer, or are required to use, long-acting injectable antipsychotic medications due to the adherence benefit. However, they may not be able to achieve adequate symptom reduction prior to experiencing treatment-limiting adverse effects from a single agent. Here, we present a patient case prescribed concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate due to patient preference in the setting of a history of nonadherence to oral medications, treatment-limiting adverse effects to long-acting injectable paliperidone, and failure to achieve adequate symptom reduction with long-acting injectable aripiprazole monotherapy.


1983 ◽  
Author(s):  
T. P. Hogan ◽  
A. George Awad ◽  
M. R. Eastwood

1983 ◽  
Author(s):  
Thomas P. Hogan ◽  
A. George Awad ◽  
Robin Eastwood

2017 ◽  
Vol 41 (S1) ◽  
pp. S369-S370
Author(s):  
L. Montemagno ◽  
M. Ludovico ◽  
A. Distefano ◽  
M. Marta Valentina ◽  
B. Mariacatena ◽  
...  

BackgroundAdherence to prescribed antipsychotic drugs is a crucial factor in predicting medium- to long-term clinical outcome in schizophrenia. A helpful approach to promote adherence in schizophrenia is the use of long-acting injectable (LAI) antipsychotics.ObjectTo evaluate:– the global functioning and the hospitalization rate occurred in the year before and in the year following the switch from a low-efficacy oral antipsychotic to either a LAI once-monthly therapy (palmitate paliperidone or olanzapine pamoate) or the corresponding oral compound (paliperidone\risperidone or olanzapine) in schizophrenic patients;– the treatment attitude and the insight in patients treated with second-generation antipsychotic (SGA)-LAIs and with the corresponding oral compounds.MethodSixty adult schizophrenic outpatients: thirty were switched to LAIs and thirty to the corresponding oral antipsychotic. We used the following scales: Drug Attitude Inventory (DAI), Schedule for the Assessment of Insight (SAI), Life Skill Profile (LSP).ResultsNumber of hospitalizations per year decreased in both groups (LAIs: from 1.3 ± 0.5 to 0.3 ± 0.5; oral: from 1.3 ± 0.5 to 0.6 ± 0.5). We found a direct association between the “hospitalization event” and the oral drug compared to the corresponding LAI formulation (P = 0.049; OR: 3.05; 95% IC: 1.01–9.26). Patient receiving LAIs achieved a more significant improvement at the LSP score compared to the oral group (P < 0.001 vs. P = 0.0034) and higher DAI (5.9 ± 4.3 vs. −1.1 ± 4.3) and SAI (8.7 ± 2.9 vs. 5.6 ± 2.1).ConclusionsOur data suggest that SGA-LAIs, improving the adherence to the treatment, may sensitively reduce costs in mental health services.Disclosure of interestThe authors have not supplied their declaration of competing interest.


Sign in / Sign up

Export Citation Format

Share Document